Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells

Abstract

The use of topiramate (TPM) in the treatment of binge-eating disorder, bulimia nervosa, and antipsychotic-induced weight gain has recently increased, however, the exact molecular basis for its effects on body weight reduction and improved glucose homeostasis, is yet to be elucidated. Here we investigated the effect and signaling pathway of TPM on glucose uptake in L6 rat skeletal muscle cells, which account for >70% of glucose disposal in the body. Intriguingly, we found that TPM (10 μ M) stimulated the rate of glucose uptake up to twofold increase. And TPM-stimulated glucose transport was inhibited with the overexpression of dominant-negative form of AMP-activated protein kinase (AMPK), an important mediator in glucose transport, implicating that AMPK-mediated pathway is involved. The TPM-stimulated glucose transport was blocked by SB203580, a specific inhibitor of AMPK downstream mediator, p38 mitogen-activated protein kinase (MAPK) protein. LY294002, an inhibitor of phosphatidylinositol (PI) 3-kinase, which is another crucial mediator in independent glucose transport pathway, did not inhibit TPM-stimulated glucose transport. We also found that TPM increased the phosphorylation level of AMPK and p38 MAPK, whereas no effect on the activity of PI 3-kinase of TPM, when assessed by PI 3-kinase assay, was observed. These results together suggest that TPM stimulates glucose transport, not via PI 3-kinase mediated, but via AMPK-mediated pathway in skeletal muscle cells, thereby contributing to the body weight regulation and glucose homeostasis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D . Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000; 8: 656–663.

    Article  CAS  Google Scholar 

  2. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335–1341.

    Article  CAS  Google Scholar 

  3. Shapira NA, Goldsmith TD, McElroy S . Treatment of binge disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368–372.

    Article  CAS  Google Scholar 

  4. Barbee JG . Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 2003; 33: 468–472.

    Article  Google Scholar 

  5. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-Month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–733.

    Article  CAS  Google Scholar 

  6. Schmidt do Prado-Lima PA, Bacaltchuck J . Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord 2002; 4: 271–273.

    Article  Google Scholar 

  7. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R . Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186–190.

    Article  CAS  Google Scholar 

  8. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65 (Suppl 7): 4–18.

    PubMed  Google Scholar 

  9. Nasrallah HA, Newcomer JW . Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (5 Suppl 1): S7–S14.

    Article  Google Scholar 

  10. Haupt DW, Newcomer JW . Risperidone-associated diabetic ketoacidosis. Psychosomatics 2001; 42: 279–280.

    Article  CAS  Google Scholar 

  11. Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillen JM, Hernández L . Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment. Mol Psychiatry 2000; 5: 70–76.

    Article  CAS  Google Scholar 

  12. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–296.

    Article  Google Scholar 

  13. Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1–93.

    CAS  PubMed  Google Scholar 

  14. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–566.

    Article  Google Scholar 

  15. Jin H, Meyer JM, Jeste DV . Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195–212.

    Article  Google Scholar 

  16. Ängehagen M, Ben-Menachem E, Rönnbäck L, Hansson E . Topiramate protects against glutamate- and kainite-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 2003; 54: 63–71.

    Article  Google Scholar 

  17. Xi X, Han J, Zhang JZ . Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 2001; 276: 41029–41034.

    Article  CAS  Google Scholar 

  18. Lemieux K, Konrad D, Klip A, Marette A . The AMP-activated protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases á and â in skeletal muscle. FASEB J 2003; 17: 1658–1665.

    Article  Google Scholar 

  19. Hardie DG, Carling D, Carlson M . The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell. Annu Rev Biochem 1998; 67: 821–855.

    Article  CAS  Google Scholar 

  20. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA . Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999; 24: 22–25.

    Article  CAS  Google Scholar 

  21. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K . Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 2005; 4: 360–369.

    Article  Google Scholar 

  22. McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim MR et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255–261.

    Article  Google Scholar 

  23. Astrup A, Toubro S . Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004; 12 (Suppl): 167S–173S.

    Article  CAS  Google Scholar 

  24. DeFronzo RA, Bonadonna RC, Ferrannini E . Pathgenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318–368.

    Article  CAS  Google Scholar 

  25. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG . Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223–228.

    Article  CAS  Google Scholar 

  26. Czech MP, Corvera S . Signaling mechanisms that regulate glucose transport. J Biol Chem 1999; 274: 1865–1868.

    Article  CAS  Google Scholar 

  27. Cortright RN, Dohm GL . Mechanisms by which insulin and muscle contraction stimulate glucose transport. Can J Appl Physiol 1997; 22: 519–530.

    Article  CAS  Google Scholar 

  28. Brozinick Jr JT, Birnbaum MJ . Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle. J Biol Chem 1998; 273: 14679–14682.

    Article  CAS  Google Scholar 

  29. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ . Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47: 1369–1373.

    CAS  PubMed  Google Scholar 

  30. Musi N, Hayashi T, Fujii N, Hirshman MF, Witters LA, Goodyear LJ . AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280: E677–E684.

    Article  CAS  Google Scholar 

  31. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM . Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in High-Fa – Fed Male Wistar rats. Am J Physiol Endocrinol Metab 2005; 289: E1015–E1022.

    Article  CAS  Google Scholar 

  32. Eichhorn J, Kayali AG, Austin DA, Webster NJ . Insulin activates phospholipase C-gamma1 via a PI-3 kinase dependent mechanism in 3T3-L1 adipocytes. Biochem Biophy Res Commun 2001; 282: 615–620.

    Article  CAS  Google Scholar 

  33. Kim MS, Lee J, Ha J, Kim SS, Kong Y, Cho YH et al. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells. Arch Biochem Biophys 2002; 401: 205–214.

    Article  CAS  Google Scholar 

  34. Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003; 278: 39653–39661.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are immensely indebted to Earl Han (medical student) for his help in preparing this manuscript. This work was supported by the grant of the Korea Heath 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A040042).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J W Kim.

Additional information

Duality of interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ha, E., Yim, S., Jung, K. et al. Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmacogenomics J 6, 327–332 (2006). https://doi.org/10.1038/sj.tpj.6500366

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500366

Keywords

Search

Quick links